Stanley E. Althof
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stanley E. Althof has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Chris G. McMahon
Australian Centre for Sexual Health, St. Leonards, New South Wales, Australia
6 shared publicationsRaymond C. Rosen
New England Research Institutes, Watertown, MA, USA
5 shared publicationsDavid L. Rowland
Department of Psychology, Valparaiso University, Valparaiso, IN, USA
3 shared publicationsDavid Rowland
Graduate School, Valparaiso University Valparaiso, IN, USA
3 shared publicationsEdgardo Becher
Division of Urology, University of Buenos Aires Buenos Aires, Argentina
3 shared publicationsFrancois Giuliano
Neuro-Uro-Andrology, Physical Medicine and Rehabilitation Department, Raymond Poincaré Hospital Garches, France
3 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (3)
A retrospective–present-day analysis on acquired premature ejaculation
Background: Men with acquired premature ejaculation (APE) develop the condition after a period of normal ejaculatory function. This is the first article to focus on the developmental course of APE. Aim: To retrospectively detail the developmental course of foreplay duration, ejaculatory latencies over multiple partnered sexual activities, and changes in PE symptomology in men with APE from age of sexual debut to the present. Methods: From March 2024 through February 2025, 411 volunteers, aged 18-80 years, responded to an online sexual health and behavior questionnaire posted on multiple social media platforms. These men also met the preliminary qualifying criteria of having PE based on responses to an abridged Premature Ejaculation Diagnostic Tool (PEDT) and meeting other inclusion criteria. Of these, 77 men (mean age = 40 years, range 19-66) met the criterion of having APE as their symptoms developed only after an extended period of normal ejaculatory control. Outcome: Significant changes in partnered ejaculatory latencies from the men’s sexual debut to the present are reported. Results: Sexual debut typically occurred around age 19, with PE first reported on average at age 31. Overall, vaginal and anal ejaculatory latencies (EL) at sexual debut were 5.98, 5.01, and 4.7 min, respectively, but the overall, vaginal and anal ELs at the present time were 1.86, 0.97, and 0.75 min (P < .001). Foreplay duration of approximately 12-13 min remained unchanged over the lifespan despite large decreases in ELs. Nearly 34% of the participants reported that their symptomology continued to worsen after it first appeared. Clinical Implications: The data highlight the major differences between present-day partnered sexual behaviors and time spent in foreplay and masturbation compared to sexual activities earlier in life. It suggests that under specific circumstances men have the ability to delay ejaculation. Strengths and Limitations: The strength of this article is its developmental perspective in terms of examining the men’s past and present sexual behaviors. The major limitations are the retrospective–present-day methodology and recruitment via social media, which could lead to sample biases and reliance on men’s recall. Conclusions: This study both confirms the presumed developmental course of ELs in men with APE and adds new insights regarding these men’s sexual experiences, including the comparability of their ELs with men having lifelong PE, the relationship between ELs and types of partnered sexual activity, and the lack of association between foreplay duration and EL. It also documents that one-third of men with APE experienced continued deterioration of their condition with age.
- 1 April 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (3)
Open AccessA retrospective–present-day analysis on acquired premature ejaculation
Background: Men with acquired premature ejaculation (APE) develop the condition after a period of normal ejaculatory function. This is the first article to focus on the developmental course of APE. Aim: To retrospectively detail the developmental course of foreplay duration, ejaculatory latencies over multiple partnered sexual activities, and changes in PE symptomology in men with APE from age of sexual debut to the present. Methods: From March 2024 through February 2025, 411 volunteers, aged 18-80 years, responded to an online sexual health and behavior questionnaire posted on multiple social media platforms. These men also met the preliminary qualifying criteria of having PE based on responses to an abridged Premature Ejaculation Diagnostic Tool (PEDT) and meeting other inclusion criteria. Of these, 77 men (mean age = 40 years, range 19-66) met the criterion of having APE as their symptoms developed only after an extended period of normal ejaculatory control. Outcome: Significant changes in partnered ejaculatory latencies from the men’s sexual debut to the present are reported. Results: Sexual debut typically occurred around age 19, with PE first reported on average at age 31. Overall, vaginal and anal ejaculatory latencies (EL) at sexual debut were 5.98, 5.01, and 4.7 min, respectively, but the overall, vaginal and anal ELs at the present time were 1.86, 0.97, and 0.75 min (P < .001). Foreplay duration of approximately 12-13 min remained unchanged over the lifespan despite large decreases in ELs. Nearly 34% of the participants reported that their symptomology continued to worsen after it first appeared. Clinical Implications: The data highlight the major differences between present-day partnered sexual behaviors and time spent in foreplay and masturbation compared to sexual activities earlier in life. It suggests that under specific circumstances men have the ability to delay ejaculation. Strengths and Limitations: The strength of this article is its developmental perspective in terms of examining the men’s past and present sexual behaviors. The major limitations are the retrospective–present-day methodology and recruitment via social media, which could lead to sample biases and reliance on men’s recall. Conclusions: This study both confirms the presumed developmental course of ELs in men with APE and adds new insights regarding these men’s sexual experiences, including the comparability of their ELs with men having lifelong PE, the relationship between ELs and types of partnered sexual activity, and the lack of association between foreplay duration and EL. It also documents that one-third of men with APE experienced continued deterioration of their condition with age.
- 8 December 2021
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (1) , 64-73
Advances and Missteps in Diagnosing Premature Ejaculation: Analysis and Future Directions
Background There are several problems with diagnostic criteria for premature ejaculation (PE) that lack objectivity, clarity and precision. They hamper accurate determination of PE prevalence estimates, investigations into the etiology of the dysfunction, impact on partners, development of validated Patient Reported Outcomes, regulatory authority oversight, and which men might benefit from specific treatment interventions. Aim We sought to review, analyze and comment on the evolution of the definitions of PE and offer suggestions for future directions for PE definitions. Our goal is to propose strategies whereby the criterion sets are useful to researchers, clinicians and governmental oversight agencies alike and bring harmony and scientific rigor among the conflicting and confusing definitions. Methods There are several premature ejaculation definitions published in the peer reviewed medical literature. The PUBMED electronic database from 1970 to 2021 was searched for published definitions. Search terms included the medical subject headings of premature ejaculation, definition and diagnosis. In chronological order, Table 1 lists the various diagnosis and criteria sets for PE. We discuss the process by which constructs, which make up diagnostic criteria sets, are operationalized and validated. Results We review definitions of PE beginning with Masters and Johnson's focus on partner orgasmic attainment and move through the nebulous and subjective criterion sets found in the early Diagnostic and Statistical Manuals and International Classification of Disease series, to the more evidenced-based definitions found in International Society of Sexual Medicine, Diagnostic and Statistical Manuals-5 and the American Urological Association (AUA) definitions. Additionally, we discuss how constructs and criteria sets have been adopted to minimize errors of inclusion and exclusion in defining disease/dysfunction. Strengths and Limitations This manuscript offers a careful chronological analysis of the published definitions of PE. This historical lens allows the reader to perceive the shifting science underlying the development of PE definitions. The manuscript is limited regarding our comments on acquired PE as evidenced-based research is incomplete. Conclusion Over the past 50 years there has been considerable forward momentum in defining PE based on well conducted scientific studies. We support the American Urological Association's modification in Intravaginal ejaculatory latency time to 2-minutes for lifelong PE, concur with the 11th revision of the International Classification of Diseases recommendation for changing the terminology from premature ejaculation to early ejaculation. We also recommend ongoing validation of definitions, moving away from the current heterosexist definition of PE based on penile-vaginal sex and urge further population based research into acquired PE to develop stronger evidenced-based criterion sets for this subtype. Althof SE, McMahon CG, Rowland DL. Advances and Missteps in Diagnosing Premature Ejaculation: Analysis and Future Directions. J Sex Med 2022;19:64–73.
- 8 December 2021
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (1) , 64-73
Advances and Missteps in Diagnosing Premature Ejaculation: Analysis and Future Directions
Background There are several problems with diagnostic criteria for premature ejaculation (PE) that lack objectivity, clarity and precision. They hamper accurate determination of PE prevalence estimates, investigations into the etiology of the dysfunction, impact on partners, development of validated Patient Reported Outcomes, regulatory authority oversight, and which men might benefit from specific treatment interventions. Aim We sought to review, analyze and comment on the evolution of the definitions of PE and offer suggestions for future directions for PE definitions. Our goal is to propose strategies whereby the criterion sets are useful to researchers, clinicians and governmental oversight agencies alike and bring harmony and scientific rigor among the conflicting and confusing definitions. Methods There are several premature ejaculation definitions published in the peer reviewed medical literature. The PUBMED electronic database from 1970 to 2021 was searched for published definitions. Search terms included the medical subject headings of premature ejaculation, definition and diagnosis. In chronological order, Table 1 lists the various diagnosis and criteria sets for PE. We discuss the process by which constructs, which make up diagnostic criteria sets, are operationalized and validated. Results We review definitions of PE beginning with Masters and Johnson's focus on partner orgasmic attainment and move through the nebulous and subjective criterion sets found in the early Diagnostic and Statistical Manuals and International Classification of Disease series, to the more evidenced-based definitions found in International Society of Sexual Medicine, Diagnostic and Statistical Manuals-5 and the American Urological Association (AUA) definitions. Additionally, we discuss how constructs and criteria sets have been adopted to minimize errors of inclusion and exclusion in defining disease/dysfunction. Strengths and Limitations This manuscript offers a careful chronological analysis of the published definitions of PE. This historical lens allows the reader to perceive the shifting science underlying the development of PE definitions. The manuscript is limited regarding our comments on acquired PE as evidenced-based research is incomplete. Conclusion Over the past 50 years there has been considerable forward momentum in defining PE based on well conducted scientific studies. We support the American Urological Association's modification in Intravaginal ejaculatory latency time to 2-minutes for lifelong PE, concur with the 11th revision of the International Classification of Diseases recommendation for changing the terminology from premature ejaculation to early ejaculation. We also recommend ongoing validation of definitions, moving away from the current heterosexist definition of PE based on penile-vaginal sex and urge further population based research into acquired PE to develop stronger evidenced-based criterion sets for this subtype. Althof SE, McMahon CG, Rowland DL. Advances and Missteps in Diagnosing Premature Ejaculation: Analysis and Future Directions. J Sex Med 2022;19:64–73.
- 1 November 2019
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 16 (11) , 1864-1865
Response to Letter to the Editor Regarding “Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?”
We wish to thank Dr. Pyke for his careful reading of our papers and his knowledgeable comments regarding the role and impact of the placebo response in the contradictory results of the cligosiban clinical trials. 1 Pyke R. Cligosiban for premature ejaculation: Success, failure or insufficiently tested. J Sex Med. 2019; 16 Abstract Full Text Full Text PDF Scopus (1) Google Scholar As Dr. Pyke notes, there were different percentages of men receiving placebo in the PEPIX, the successful trial (33%), and PEDRIX, the unsuccessful trial (20%). 2 Althof S. Osterloh I.H. Muirhead G.J. et al. The oxytocin antagonist cligosiban fails to prolong intravaginal ejaculatory latency in men with lifelong premature ejaculation: Results of a randomized, double-blind, placebo-controlled phase IIb trial (PEDRIX). J Sex Med. 2019; 16 : 1188-1198 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar , 3 McMahon C. Althof S. Rosen R. et al. The oxytocin antagonist cligosiban prolongs intravaginal ejaculatory latency and improves patient-reported outcomes in men with lifelong premature ejaculation: Results of a randomized, double-blind placebo-controlled proof-of-concept trial (PEPIX). J Sex Med. 2019; 16 : 1178-1187 Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar In the unsuccessful trial, the placebo response was greater (43.1-second or 1.8-fold) than in the successful trial (16.4-second or 1.1-fold).
- 1 November 2019
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 16 (11) , 1864-1865
Response to Letter to the Editor Regarding “Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?”
We wish to thank Dr. Pyke for his careful reading of our papers and his knowledgeable comments regarding the role and impact of the placebo response in the contradictory results of the cligosiban clinical trials. 1 Pyke R. Cligosiban for premature ejaculation: Success, failure or insufficiently tested. J Sex Med. 2019; 16 Abstract Full Text Full Text PDF Scopus (1) Google Scholar As Dr. Pyke notes, there were different percentages of men receiving placebo in the PEPIX, the successful trial (33%), and PEDRIX, the unsuccessful trial (20%). 2 Althof S. Osterloh I.H. Muirhead G.J. et al. The oxytocin antagonist cligosiban fails to prolong intravaginal ejaculatory latency in men with lifelong premature ejaculation: Results of a randomized, double-blind, placebo-controlled phase IIb trial (PEDRIX). J Sex Med. 2019; 16 : 1188-1198 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar , 3 McMahon C. Althof S. Rosen R. et al. The oxytocin antagonist cligosiban prolongs intravaginal ejaculatory latency and improves patient-reported outcomes in men with lifelong premature ejaculation: Results of a randomized, double-blind placebo-controlled proof-of-concept trial (PEPIX). J Sex Med. 2019; 16 : 1178-1187 Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar In the unsuccessful trial, the placebo response was greater (43.1-second or 1.8-fold) than in the successful trial (16.4-second or 1.1-fold).
- 1 August 2019
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 16 (8) , 1188-1198
The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)
Introduction: Cligosiban is an orally administered, centrally penetrant oxytocin receptor antagonist being developed to treat premature ejaculation (PE). Aim: To determine the efficacy of 3 dose levels of cligosiban caplets to prolong intravaginal ejaculation latency time (IELT) and improve patient-reported outcomes in men with lifelong PE. Methods: Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline assessments. Patients were eligible for the study if their stopwatch-assessed IELT was ≤1 minute in ≥75% of intercourse attempts and if they met other diagnostic criteria for lifelong PE. Eligible patients (target 220 evaluable) were randomized to double-blind cligosiban 400, 800, or 1200 mg or matching placebo caplets (to be taken 1 to 6 hours prior to sexual activity). Assessments were conducted at 2, 4, and 8 weeks. Main Outcome Measure: Efficacy measures were comprised of IELT, self-rating of ejaculation control and ejaculation-related distress (recorded in an electronic diary after each intercourse attempt), premature ejaculation profile, Patient’s Global Impression of Severity, and the Clinical Global Impression of Change. Results: There were no clinically or statistically significant differences between cligosiban (at any dose level) and placebo for the primary endpoint (change in geometric IELT) or any of the secondary endpoints. Cligosiban was well tolerated with a side-effect profile similar to placebo. Clinical Implications: This Phase IIb study failed to demonstrate the potential for cligosiban, an oxytocin antagonist, to successfully treat symptoms of severe lifelong PE at doses up to 1200 mg. Strengths and Limitations: This was a Phase IIb, randomized, double-blind, placebo-controlled study that was adequately powered but failed to detect a clinically meaningful or statistical difference in change in IELT between cligosiban at 3 dose levels and placebo. This is in contrast to a similarly designed proof-of-concept study where cligosiban was flexibly dosed at doses up to 800 mg and did demonstrate clinically meaningful and statistically significant changes in efficacy parameters. The reasons for this disparity are not known. Conclusions: Cligosiban was well tolerated but failed to demonstrate efficacy for the treatment of men with lifelong PE at doses up to 1200 mg.
- 1 August 2019
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 16 (8) , 1188-1198
The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)
Introduction: Cligosiban is an orally administered, centrally penetrant oxytocin receptor antagonist being developed to treat premature ejaculation (PE). Aim: To determine the efficacy of 3 dose levels of cligosiban caplets to prolong intravaginal ejaculation latency time (IELT) and improve patient-reported outcomes in men with lifelong PE. Methods: Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline assessments. Patients were eligible for the study if their stopwatch-assessed IELT was ≤1 minute in ≥75% of intercourse attempts and if they met other diagnostic criteria for lifelong PE. Eligible patients (target 220 evaluable) were randomized to double-blind cligosiban 400, 800, or 1200 mg or matching placebo caplets (to be taken 1 to 6 hours prior to sexual activity). Assessments were conducted at 2, 4, and 8 weeks. Main Outcome Measure: Efficacy measures were comprised of IELT, self-rating of ejaculation control and ejaculation-related distress (recorded in an electronic diary after each intercourse attempt), premature ejaculation profile, Patient’s Global Impression of Severity, and the Clinical Global Impression of Change. Results: There were no clinically or statistically significant differences between cligosiban (at any dose level) and placebo for the primary endpoint (change in geometric IELT) or any of the secondary endpoints. Cligosiban was well tolerated with a side-effect profile similar to placebo. Clinical Implications: This Phase IIb study failed to demonstrate the potential for cligosiban, an oxytocin antagonist, to successfully treat symptoms of severe lifelong PE at doses up to 1200 mg. Strengths and Limitations: This was a Phase IIb, randomized, double-blind, placebo-controlled study that was adequately powered but failed to detect a clinically meaningful or statistical difference in change in IELT between cligosiban at 3 dose levels and placebo. This is in contrast to a similarly designed proof-of-concept study where cligosiban was flexibly dosed at doses up to 800 mg and did demonstrate clinically meaningful and statistically significant changes in efficacy parameters. The reasons for this disparity are not known. Conclusions: Cligosiban was well tolerated but failed to demonstrate efficacy for the treatment of men with lifelong PE at doses up to 1200 mg.
- 2 July 2019
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 16 (8) , 1226-1235
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide
Background: Responder analyses are used to determine whether changes that occur during a clinical trial are clinically meaningful; for subjective endpoints such as those based on patient-reported outcomes (PROs), responder analyses are particularly useful. Aim: To identify the minimal clinically important difference (MCID) for selected scores on questionnaires assessing female sexual functioning and to use these differences to analyze the response in a large, controlled, phase 2b, dose-finding study of bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD) and mixed HSDD/female sexual arousal disorder (FSAD). Methods: The responder analyses were performed for the change from baseline to end of study for a total of 7 endpoints. Each PRO endpoint was assessed using at least 1 of 4 types of responder analyses: a planned analysis anchored to MCIDs based on expert estimates (historical anchors); post hoc analyses based on self-reported global benefit; receiver operating characteristic (ROC) curves; and cumulative distribution function. The prespecified analysis groups were all female sexual dysfunction (FSD)-based diagnoses (all study participants), those with HSDD alone, and a combined group of those with FSAD alone plus those with mixed HSDD/FSAD. Post hoc analyses were also performed for subjects with mixed HSDD/FSAD with a primary diagnosis of HSDD. Outcomes: MCIDs based on the ROC curves for changes in Female Sexual Function Index–desire domain, Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) total score, FSDS-DAO item 13 and 14 scores, and number of satisfying sexual events. Results: Outcomes matched those based on input from clinical experts. For all 7 endpoints, responder rates at the 1.75 mg dose in the overall modified intention-to-treat population achieved statistical significance compared with placebo (P ≤ .03). Clinical Implications: These responder definitions were subsequently used in the bremelanotide phase 3 registration studies (RECONNECT) that evaluated the safety and efficacy of the bremelanotide 1.75 mg subcutaneous dose in premenopausal women with HSDD. Strengths & Limitations: MCIDs for this study were based on changes from a single-blind phase to account for changes due to the placebo effect. These analyses were restricted to a study population composed only of premenopausal women with a clinical diagnosis of HSDD and/or FSAD and were based on data from the same clinical trial. Conclusion: Bremelanotide was safe and well tolerated and demonstrated significant improvement in efficacy vs placebo in the phase 2b trial. The multiple responder analyses offer a valuable approach for determining clinically important effects of bremelanotide for HSDD and FSAD.
- 2 July 2019
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 16 (8) , 1226-1235
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide
Background: Responder analyses are used to determine whether changes that occur during a clinical trial are clinically meaningful; for subjective endpoints such as those based on patient-reported outcomes (PROs), responder analyses are particularly useful. Aim: To identify the minimal clinically important difference (MCID) for selected scores on questionnaires assessing female sexual functioning and to use these differences to analyze the response in a large, controlled, phase 2b, dose-finding study of bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD) and mixed HSDD/female sexual arousal disorder (FSAD). Methods: The responder analyses were performed for the change from baseline to end of study for a total of 7 endpoints. Each PRO endpoint was assessed using at least 1 of 4 types of responder analyses: a planned analysis anchored to MCIDs based on expert estimates (historical anchors); post hoc analyses based on self-reported global benefit; receiver operating characteristic (ROC) curves; and cumulative distribution function. The prespecified analysis groups were all female sexual dysfunction (FSD)-based diagnoses (all study participants), those with HSDD alone, and a combined group of those with FSAD alone plus those with mixed HSDD/FSAD. Post hoc analyses were also performed for subjects with mixed HSDD/FSAD with a primary diagnosis of HSDD. Outcomes: MCIDs based on the ROC curves for changes in Female Sexual Function Index–desire domain, Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) total score, FSDS-DAO item 13 and 14 scores, and number of satisfying sexual events. Results: Outcomes matched those based on input from clinical experts. For all 7 endpoints, responder rates at the 1.75 mg dose in the overall modified intention-to-treat population achieved statistical significance compared with placebo (P ≤ .03). Clinical Implications: These responder definitions were subsequently used in the bremelanotide phase 3 registration studies (RECONNECT) that evaluated the safety and efficacy of the bremelanotide 1.75 mg subcutaneous dose in premenopausal women with HSDD. Strengths & Limitations: MCIDs for this study were based on changes from a single-blind phase to account for changes due to the placebo effect. These analyses were restricted to a study population composed only of premenopausal women with a clinical diagnosis of HSDD and/or FSAD and were based on data from the same clinical trial. Conclusion: Bremelanotide was safe and well tolerated and demonstrated significant improvement in efficacy vs placebo in the phase 2b trial. The multiple responder analyses offer a valuable approach for determining clinically important effects of bremelanotide for HSDD and FSAD.
- 29 August 2018
- Published by Springer Nature
- p. 33-40
Patient-Reported Outcomes in Sexual Medicine
- 1 February 2018
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 15 (2) , 115-117
Linguistic and Cultural Validation of Patient-Reported Outcomes Used in Clinical Trials
- 1 February 2018
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 15 (2) , 115-117
Linguistic and Cultural Validation of Patient-Reported Outcomes Used in Clinical Trials
- 1 December 2017
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (12) , 1463-1491
Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14
Introduction: Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner. Aims: To review the literature and describe the best practices for assessing and treating women with hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Methods: The committee undertook a comprehensive review of the literature and discussion among themselves to determine the best assessment and treatment methods. Results: Using a biopsychosocial lens, the committee presents recommendations (with levels of evidence) for assessment and treatment of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Conclusion: The numerous significant strides in FSD that have occurred since the previous International Consultation of Sexual Medicine publications are reviewed in this article. Although evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, the biological and psychological factors are artificially separated for review purposes. We recognize that best outcomes are achieved when all relevant factors are identified and addressed by the clinician and patient working together in concert (the sum is greater than the whole of its parts).
- 1 December 2017
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (12) , 1463-1491
Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14
Introduction: Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner. Aims: To review the literature and describe the best practices for assessing and treating women with hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Methods: The committee undertook a comprehensive review of the literature and discussion among themselves to determine the best assessment and treatment methods. Results: Using a biopsychosocial lens, the committee presents recommendations (with levels of evidence) for assessment and treatment of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Conclusion: The numerous significant strides in FSD that have occurred since the previous International Consultation of Sexual Medicine publications are reviewed in this article. Although evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, the biological and psychological factors are artificially separated for review purposes. We recognize that best outcomes are achieved when all relevant factors are identified and addressed by the clinician and patient working together in concert (the sum is greater than the whole of its parts).
- Open Access
- 1 August 2016
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 5 (4) , 470-474
Patient reported outcomes in the assessment of premature ejaculation
The term ‘Patient Reported Outcome’, abbreviated as PRO, was introduced by the US Food and Drug Administration (FDA) which proposed guidance on the development and validation of PROs. Previously PROs were known as self-report diaries, event-logs, self-administered questionnaires, and clinician administered rating scales. PROs seek to capture the subjective perceptions of patients and/or partner’s related to their specific symptoms, degree of bother, efficacy of a medication or psychotherapy intervention, and quality of life issues related to a specific condition. This article reviews the essential psychometric and regulatory agency requirements in the development of PROs. The constructs of reliability, various forms of validity, sensitivity, and specificity as well as concerns with translating a PRO into a different language are reviewed. Three PROs, the Premature Ejaculation Profile (PEP), the Index of Premature Ejaculation (IPE) and the Premature Ejaculation Diagnostic Tool (PEDT) all used in the assessment of premature ejaculation (PE) are discussed. These questionnaires meet or exceed all the psychometric requirements and have been employed in clinical trials and observational studies of men with PE. The article concludes on discussing some of the limitations of PRO use and recommendations for the future.
- 1 August 2016
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 5 (4) , 470-474
Open AccessPatient reported outcomes in the assessment of premature ejaculation
The term ‘Patient Reported Outcome’, abbreviated as PRO, was introduced by the US Food and Drug Administration (FDA) which proposed guidance on the development and validation of PROs. Previously PROs were known as self-report diaries, event-logs, self-administered questionnaires, and clinician administered rating scales. PROs seek to capture the subjective perceptions of patients and/or partner’s related to their specific symptoms, degree of bother, efficacy of a medication or psychotherapy intervention, and quality of life issues related to a specific condition. This article reviews the essential psychometric and regulatory agency requirements in the development of PROs. The constructs of reliability, various forms of validity, sensitivity, and specificity as well as concerns with translating a PRO into a different language are reviewed. Three PROs, the Premature Ejaculation Profile (PEP), the Index of Premature Ejaculation (IPE) and the Premature Ejaculation Diagnostic Tool (PEDT) all used in the assessment of premature ejaculation (PE) are discussed. These questionnaires meet or exceed all the psychometric requirements and have been employed in clinical trials and observational studies of men with PE. The article concludes on discussing some of the limitations of PRO use and recommendations for the future.
- Open Access
- 1 August 2016
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 5 (4) , 475-481
Psychosexual therapy for premature ejaculation
Premature ejaculation (PE) is a male sexual dysfunction that creates considerable anguish for the man, his partner and their relationship. PE is not one disorder but includes the four subtypes (lifelong, acquired, natural and subjective) each with unique psychological concerns and issues. Psychological treatment for men and couples with PE addresses sexual skills/techniques but also focuses on issues of self-esteem, performance anxiety and interpersonal conflict. The outcome studies for psychotherapy alone are difficult to interpret and compare because of poor methodological design (lack of control groups, small sample size, poor outcome measures and lack of follow-up). However, the few studies that surmount these methodological hurdles suggest that psychological intervention offers men and couples a promising treatment option. Combination pharmaco- and psychotherapy is the most promising intervention for lifelong and acquired PE and offers superior efficacy to drug alone. This is because men and couples learn sexual skills, address the intrapsychic, interpersonal and cognitive issues that precipitate and maintain the dysfunction.
- 1 August 2016
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 5 (4) , 475-481
Open AccessPsychosexual therapy for premature ejaculation
Premature ejaculation (PE) is a male sexual dysfunction that creates considerable anguish for the man, his partner and their relationship. PE is not one disorder but includes the four subtypes (lifelong, acquired, natural and subjective) each with unique psychological concerns and issues. Psychological treatment for men and couples with PE addresses sexual skills/techniques but also focuses on issues of self-esteem, performance anxiety and interpersonal conflict. The outcome studies for psychotherapy alone are difficult to interpret and compare because of poor methodological design (lack of control groups, small sample size, poor outcome measures and lack of follow-up). However, the few studies that surmount these methodological hurdles suggest that psychological intervention offers men and couples a promising treatment option. Combination pharmaco- and psychotherapy is the most promising intervention for lifelong and acquired PE and offers superior efficacy to drug alone. This is because men and couples learn sexual skills, address the intrapsychic, interpersonal and cognitive issues that precipitate and maintain the dysfunction.